UK Criteria for Uterus Transplantation: A review

Dr N Hammond-Browning, PhD
Senior Lecturer in Law, University of Gloucestershire
School of Law, University of Gloucestershire, Oxstalls Campus, Oxstalls Lane, Longlevens, Gloucester, GL2 9HW
nhammondbrowning@glos.ac.uk

Abbreviations:
ART – Assisted Reproductive Treatment
AUF – Absolute Uterine Factor Infertility
UTx – Uterus Transplantation

Abstract:

Absolute Uterine Factor Infertility (AUFI) is the final hurdle for assisted reproductive treatments. Uterus transplant trials are happening worldwide; in order to advance the debate around uterine transplantation (UTx) this article considers selection criteria for clinical trials from a UK perspective and makes recommendations for future selection criteria for UTx treatment. Recommendations advanced include the use of donor eggs, access for single women and women in same-sex relationships, prohibiting participation of women who are already mothers, and a preference for deceased donors and bioengineered uteri. With UTx treatment on the horizon it is important to proactively consider future selection criteria.

Keywords:
Uterus transplantation; selection criteria; clinical trials; treatment

Tweetable Abstract:
Review of UK selection criteria for clinical trials for uterus transplantation; recommendations for the future

**Main text:**

Uterus transplants (UTx) came to the world’s attention in October 2014 when a team of researchers in Sweden announced the first birth following UTx. Heralded as a treatment for women who suffer from Absolute Uterine Factor Infertility (AUFI), some women may consider UTx as their only reproductive option; adoption or surrogacy may not be a viable option for them, whether due to personal, legal, financial, ethical, or religious reasons. Prior to the first research trial in Sweden, there had been two previous attempts at human UTx. The first, conducted with a living donor in Saudi Arabia in 2000, was removed after 99 days, the second occurred in Turkey in 2011 with donation from a deceased donor. The latter has resulted in two early pregnancies that have ended in miscarriage. The first UTx in the U.S. occurred in February 2016 at the Cleveland Clinic, closely followed by Baylor University Medical Center at Dallas performing four transplants from anonymous living donors in September 2016. Two births to date have been reported by the Baylor team. The first baby to be born following UTx from a deceased donor was born in Brazil in 2017. At the time of writing, approximately 60 transplants have been performed worldwide, with 13 children born. In the UK, Womb Transplant UK, is to start clinical trials imminently. With research teams worldwide it is evident that there is considerable medical interest in developing UTx as a treatment for AUFI.
In order to advance the debate around this temporary transplant, this original article explores the UK selection criteria for UTx clinical trials, with the aim to investigate how some of the recipients’ criteria may need to be transformed to comply with the UK legal framework when UTx becomes a safe and effective treatment for AUFI. The selection of donors for UTx is then considered. Recommendations for future UK selection criteria for UTx treatment are advanced. It is noted that the author is an outside observer and is not part of a medical team investigating UTx. The discussed selection criteria are from publicly available sources.

Selection Criteria to Participate in a Uterus Transplant Clinical Trial

FIGO published limited UTx guidelines in 2009, followed in early 2012 by the Montreal Criteria, which were the first criteria to consider the ethical feasibility of UTx. Criteria were more broadly agreed in Indianapolis at a meeting of medical experts and stakeholders in 2011 and published November 2012. A number of ‘way markers’ were agreed that needed to be ‘...considered to provide sufficient scientific and ethical justification for taking human UTn from a rare oddity, to a recognized and reasonable addition to the armamentarium of assisted reproductive technologies...’ These ‘way markers’ make up the Indianapolis Consensus, and include the need for women to provide their own eggs, a recommendation of 2-3 years to be in receipt of the donated uterus, the need to remove the donated uterus after a successful pregnancy, and to encourage women to pursue alternatives to UTx. Worldwide, eligibility criteria have developed along these lines and in accordance with the laws of the relevant jurisdiction (for example, see Table S1).
UK Selection Criteria

a) Own ovum

The UK criteria, as with all UTx trials worldwide, require all recipients to produce their own ovum. According to the Swedish team, the reasons that recipients need to undergo IVF is ‘…to exclude any sterility factor related to fertilization failure and to cryopreserve embryos for transfer more than 12 months after transplantation…’\(^1\) In addition, there is an upper age limit of 38 years (40 years if embryos frozen before 38 years of age), presumably because the women that participate have to be able to produce their own ovum, and the number, as well as their quality, declines rapidly from 35 years onwards.\(^1\)\(^2\) As noted by Huet, et al., ‘…patients older than 35-40 years are not ideal candidates for UTx at the present time. Such patients are more prone to multiple complications of pregnancy. …Furthermore, the ovarian reserve diminishes beyond age 35, thus increasing the possibility of a poor response to ovarian stimulation…’\(^1\)\(^3\) So at present, any woman who lacks ovaries as well as a uterus is not eligible for the UK research trial.

The Swedish team require recipients to produce ovum in order to rule out infertility for reasons other than AUFI. It is noticeable that there is no requirement for the recipient to have a partner who is able to produce healthy sperm for the IVF process. However, for those women with AUFI, the reasoning behind the criteria appears irrelevant. Even if they are able to produce their own ovum, they cannot gestate.
In the UK trial all recipients have to undergo IVF to produce a minimum of 10 embryos prior to transplantation. Other trials vary between 2 and 10 embryos, whilst the American Society for Reproductive Medicine recommends ‘a sufficient number of good prognosis embryos’.\(^\text{14}\) It is foreseeable that a recipient’s supply of frozen embryos will run out before a successful pregnancy is achieved. No literature states what happens in this situation. It is predicted that the recipient would be required to undergo more cycles of ovarian stimulation to continue to comply with the inclusion criteria; this may be medically difficult to achieve due to the implanted uterus. Once the UK team demonstrates proof of concept, it will be difficult to justify limiting UTx to women able to produce their own ovum due to the UK legal recognition of, and access to, donor gametes. Donor sperm is permitted in the UK trial; the requirement for the recipient to produce her own ovum is not legally justified, as other infertile women can use donor ovum in other assisted reproductive treatments (ART). However, in a clinical trial setting this may be medically justified.

From published literature it is uncertain why the use of donor ovum is prohibited in the UK clinical trial. The prohibition conflicts with the UK reproductive regulations that permit gamete donation for reproductive purposes.\(^\text{15}\) Women unable to produce their own genetic material are unfairly excluded from clinical trials, but looking to the future ought not to be excluded from UTx treatment. This reflects both the regulatory and the societal position in the UK; the use of donor gametes is well regulated, widely recognised and socially accepted.

It is recommended that all recipients have the opportunity to utilise donor gametes at any point in the UTx process. This corresponds with the UK legislative provisions as
well as promoting reproductive autonomy. Unless medically justified, the inability to produce ovum should not act as an exclusion criterion.

b) Requirement to have a partner

For the UK trial, it is preferable that the recipient is in a stable and loving relationship at the time of the procedure due to the support needed after surgery; donor sperm may also be used, thereby opening up the research trial to single women and female same-sex couples.\textsuperscript{16} The preference for a partner recognises the support needed for the complex, invasive and lengthy process involved. Before commencing ART in the UK, there is a legal requirement to take account of the welfare of any child who may be born as a result of the treatment, including the need of that child for supportive parenting.\textsuperscript{15} It is not necessary for a woman to have a sexual partner to provide that support, nor is there a requirement to have two parents. Therefore, so long as the recipient has a good support system, then she should be able to participate in the trial.\textsuperscript{17} Prima facie, the preference for a partner requirement in the trial setting appears inconsistent with UK legislation, and would need special justification if it were to continue as an eligibility criterion beyond the research realm. Whilst the same arguments can be presented with regards to research trials, I recognise that the UK team have received research ethics committee approval on the basis of the agreed selection criteria and must be adhered to during the clinical trial. As with all organ transplants, it is preferable for potential recipients to show that they have support, whether that is from a sexual partner, a family member, or a close friend, to help maximise the success of the transplant. If UTx is proven to be safe, then in order to
promote the reproductive autonomy of all women affected by AUFI, there should not be a requirement to have a partner.

Therefore, it is recommended that women with AUFI are able to access UTx regardless of their relationship status, provided that they can demonstrate that they have a good support system, and account must be taken of the welfare of the child that may be born as a result of treatment. The ability to demonstrate a support network is a more suitable criterion and would conform to the legislative framework.

c) Age and Female

The UK trial explicitly requires that recipients are female and aged 24-38 yrs. Alongside the requirement to use one’s own ovum, the age limit is medically justified due to the decrease in pregnancy success rates with increasing maternal age. Nevertheless, if donor ovum is permitted, or the recipient’s ovum was frozen before the upper age limit, then the upper age limit may need to be revised. An appropriate guide is 42 years if NHS funded (in accordance with NICE IVF guidelines), and 50 years if privately funded.

Currently, there are medical and anatomical reasons for limiting UTx to biological females; however, the medical barriers to UTx in transgender women and men do not appear to be insurmountable. Continuation of the debate around UTx and access for transgender women (and men) is fundamental; the use of donor ovum alongside UTx could provide an opportunity for transgender women to gestate their own genetically related child, (if sperm was frozen prior to gender reassignment surgery).
Under the Equality Act 2010 transgender people are afforded explicit protection from direct and indirect discrimination, as such it will be legally impermissible to deny access to transgender women purely because of their gender identity. However, if the goal of UTx is solely reproduction, this may justify limiting UTx to cisgender women. This is because legally all recipients of UTx in the UK must be biologically female. UK law prohibits the transfer of human embryos to anyone other than a woman who has been a woman from birth. Therefore, even if medically feasible and ethically supported, UTx would not be able to serve its reproductive purpose in transgender women. Conversely, if UTx has goals other than reproductive, such as offering an opportunity to realign gender identity, then it may be appropriate to provide UTx to transgender women, men, and to women with AUFI who do not seek to reproduce.

I acknowledge the emerging debate around transgender women and UTx, however, all recipients in the UK must be biologically female as UK law currently prohibits the transfer of human embryos to anyone other than a woman who has been a woman from birth. Human rights challenges are likely and proactive debate needed before UTx for transgender women (and men) proceeds. The existing UK selection criteria for UTx legally conform and would need to continue in this form when UTx is provided as a reproductive treatment option.

It is recommended that research teams investigate the legal frameworks within which they are working; if it is legally prohibited to transfer embryos to anyone other than a biological female then medics either need to work with legislators to reform the law (if desired) or cease work that is intentionally designed to perform UTx in biologically male bodies.
d) Not already a mother

Adoption and surrogacy are options for parenthood in the UK. Recipients must be fully informed of the alternative paths to parenthood open to them; this is included in the procedures of research teams worldwide.\textsuperscript{11} Gestational surrogacy achieves the same outcome as UTx, a genetically related child. It is equally important that adoption is taken seriously as an option to become a parent, as these are children already in existence who need a stable family environment.\textsuperscript{20}

It is recognised that adoption and surrogacy may not be a simple option to pursue. Although altruistic gestational surrogacy is legally permitted in the UK, it lacks legal certainty for intended parents. Unenforceability of surrogacy arrangements, birth mothers recognised as the legal mother, and the need for parental orders to transfer legal parenthood, can result in apprehensive and reluctant intended parents.\textsuperscript{15,21,22} Equally, women may not feel comfortable shifting the burden of gestation to another, in order to achieve her own personal aim of becoming a mother, or they may desire the gestational and social experience of pregnancy. The adoption avenue may not be open to some women, does not have enough ‘desirable’ babies for adoption, or is very difficult to access due to restrictions in the adoption process.

Even where surrogacy and adoption are accessible, some women may strongly feel that gestating their own child is the only option for them, and so UTx is the sole reproductive solution.
The medical motivation for conducting UTx is to find a treatment for women with AUFI. The goal is to successfully perform UTx and to have a live birth, thereby providing another route to motherhood. A gestational experience was not the early motivation for pursuing UTx. In 2008 it was stated that, “Uterine transplantation would not be undertaken to fulfil a woman’s desire to experience pregnancy. It would not be performed to allow a woman to carry a pregnancy, or to give birth per se, but rather to allow the couple to have a child and thereby a family.” This is a rare example in the scientific literature unambiguously stating that motherhood is the medical aim of UTx. This is further evidenced by the UK criteria explicitly excluding recipients who are already mothers, including by adoption or surrogacy, and the recipients in the Swedish trial had no previous children.

The importance of experiencing gestation must not be underestimated; the first woman to undergo UTx in the U.S. chose to volunteer, and was accepted, for a UTx trial even though she and her husband were already parents to three adopted children. A recent quantitative study also supports the view that women with AUFI who are already mothers are interested in accessing UTx.

As noted, Womb Transplant UK excludes from their trial any woman who is already a mother. If account is taken of existing children of the family, the medical risks of this experimental procedure further justify excluding women who are already mothers.

If existing motherhood is to be utilised as selection criteria beyond research trials, clarification of the goal of UTx is vital. Gestation and motherhood appear inextricably linked; it may seem inconceivable that someone would want UTx without subsequently
attempting gestation. Yet there may be some women, including transgender women, who may desire UTx without subsequent gestation.

Lotz suggests that UTx has three goals ‘(a) to become a parent and raise a child; (b) to have a biologically related child; and (c) to experience gestation’. Moving forward, if it is more widely recognised that one of the goals of UTx is to experience gestation, this calls for UTx to be available to all women with AUFI who have not had the opportunity to experience gestation. In contrast, if the goal of UTx is motherhood, selection criteria could exclude women who are already mothers by any means.

There is a need for a clear definition that addresses the medical goal of UTx as well as the goal(s) of the potential recipients; it is imperative that the justifications for UTx are updated to reflect those different goals. Due to a likely lack of available uteri, scarce resources, and the risks to recipients, it is recommended that at this time UTx is only offered to women who are not already mothers.

e) Donors

It should not be forgotten that UTx involves two women – a recipient and a donor. Whether there should be a preference for living or deceased donors is subject to ethical and medical debate; research trials vary. The Swedish trial succeeded with known living donors. In the U.S., Baylor Medical Center has performed UTx with anonymous living donors with two births reported. In Turkey, the first transplant from a deceased donor has so far failed to result in a successful pregnancy, and in 2016 the Cleveland Clinic in the U.S. had to remove a uterus from a deceased donor soon
after transplantation. Proof of concept with UTx from a deceased donor has now been shown with a birth in Brazil. In the UK, Womb Transplant UK has approval to conduct research trials with both deceased and living donors.

Obviously, the removal of a uterus from a deceased donor is the least medically risky option, ‘…the surgery for retrieval of organs being far less complex, and there being no risk of harm to the donor.’ The principal (non-medical) concern with deceased donation is the consent process; Caplan et al. argue that few women would have thought about donating their uterus upon death, and a woman may not be as willing to donate her reproductive organs, as she may distinguish it from her other organs.

As such, they argue that ‘explicit consent’ for uterus donation prior to death is preferred. In a recent French study that sought explicit consent from family members to retrieve uterus from brain dead donors, none of the families asked refused consent. As such, provided that explicit consent has been obtained from either the donor prior to death or family members, the use of uteri from deceased donors is legally and ethically unproblematic. England and Wales operate two different organ donation schemes, the former requires donors to opt-in, whilst the latter operates an opt-out deemed consent scheme. However, even under the deemed consent scheme, explicit consent is required for the donation and transplantation of a uterus from living and deceased donors.

There are other limitations with the deceased donor model; the inability to schedule the procedure thereby lengthening the period of cold ischemia, the lack of time available for pre-transplant evaluation, and the scarcity of donors are three notable limitations. The scarcity of suitable deceased donors is a serious limitation, which has led to many research teams proceeding with living donors.
Ethical concerns and medical complications increase with the use of living donors. The need to preserve vascular support to ensure successful transplantation requires a radical hysterectomy; this is highly invasive and complex encompassing a range of risks that even in skilled hands cannot be completely avoided. Research highlights risks for living donors including complications with the hysterectomy, ovarian dysfunction, a decrease in quality of life, mental problems, sexual dysfunction, and urogenital complications.\textsuperscript{2,11,35,36} The willingness of women to act altruistically and subject themselves to risks when there is no corresponding medical benefit to them is admirable, yet should raise concerns. Altruism in the medical context is highly regarded, but social influences and factors along with donor motivations must be investigated prior to inclusion in a trial.

If the living donor is a relative, then particular care must be taken with donor consent due to the risk of emotional pressures and coercion within the familial environment as well as societal pressures.\textsuperscript{37}

The advantage of living donors is time; allowing for necessary medical checks, and scheduling of the surgeries. It is vital that the donors are fully informed of the health risks to themselves and recipients, as well as the time commitment that they are making for the pre-surgery tests, the surgery itself, and the recovery period. The donor may also feel conflicted about donating an organ that she no longer needs but which is a symbol of femininity.\textsuperscript{38,39} With increasing awareness of UTx as a treatment for AUFI, there may be a corresponding social influence for female relatives to donate to a family member with AUFI. Whilst it is clear that donors can withdraw their consent
at any time prior to the donation, donors may feel unable to do so, particularly if they know the potential recipient. As Kisu et al argue, support systems must be established ‘...to ensure voluntary decision making and long-term follow up and care for donors, similar to the support available for recipients.'

As noted by Catsanos et al, anonymous living donation could reduce the risk of coerced consent, whereas Dickens questions the motivations behind anonymous donation: ‘Outside a family relationship or close friendship, the willingness of a woman to undertake hazards of non-therapeutic removal of her uterus to promote an unrelated woman’s childbearing raises questions of her motivation.’ Whilst questions over coercion may be resolved with anonymous donation, the health risks of a complex hysterectomy procedure must not be overlooked when informing, and obtaining, express consent.

The use of deceased donors or bioengineered uteri would overcome all of the concerns expressed in relation to living donors. At present, provided that express consent has been given, and the removal of life saving organs remains a priority, deceased donation is preferred. With the recent birth of a child after UTx from a deceased donor, research teams worldwide may find it harder justifying the use of living donors in trials. In the future, bioengineered uteruses will remove the need for immunosuppressant drugs (if the recipient’s own cells are used to grow the bioengineered uterus), uteri can be grown ‘to order’, and surgery can be scheduled. There would be no risks to a living donor, no familial or social pressure to donate, and no questions around appropriate consent. For these reasons, the Swedish team has
already started research in animal models to grow and transplant bioengineered uteruses.\textsuperscript{42}

In light of all the risks for living donors, it is recommended that UTx be performed with deceased donors who have expressly given consent for uterus donation, or bioengineered uteruses.

Conclusion

Successful UTx and live births is a major breakthrough for women with AUFI who desire gestation in order to achieve motherhood. Questions have been raised with regards to recipients' selection criteria for UTx when it becomes available as a treatment for AUFI.

Nonetheless, based on the development of other reproductive treatments and the rapid progress being made in UTx, it is highly likely that UTx treatment will soon come to fruition. In order to continue the debate, I have examined the UK selection criteria for UTx trials and made recommendations going forward (Table S2). These include the use of donor eggs, access for single women and women in same-sex relationships, prohibiting the participation of women who are already mothers, and the inclusion of deceased donors and bioengineered uteri.

This original analysis builds upon the work in this fledgling area of healthcare, bioethics and law. These recommendations are important for formulating regulatory and ethical frameworks in which UTx can proceed.
Acknowledgments: Thanks to the participants of the first State of the Art meeting of the International Society for Uterus Transplantation for their feedback and comments on a presented draft of this paper.

Disclosure of Interests: None declared

No ethical approval was required for this literature-based review

No funding was received

Dr N Hammond-Browning is the sole author – conception, planning, carrying out, analysis and write up has been solely performed by Dr N Hammond-Browning

References:

12. ASRM. *Age and Fertility: A Guide for Patients* 
https://www.asrm.org/BOOKLET_Age_And_Fertility/ Accessed August 26, 2016
15. The Human Fertilisation and Embryology Act 1990 (as amended)
16. Womb Transplant UK. *Who is Eligible?* http://wombtransplantuk.org/about/who-is-eligible Accessed September 26, 2018
20. Lotz M. *Uterus Transplantation as radical reproduction: Taking the adoption alternative more seriously* (2018) 32(8) Bioethics 499-508
21. Surrogacy Arrangements Act 1985
31. Human Tissue Act 2004
32. Human Transplantation (Wales) Act 2013
33. Human Transplantation (Excluded Relevant Material)(Wales) Regulations 2015

42. Hellström M. *Bioengineered uterine tissue supports pregnancy in rat model* (2016) Reproductive Science 106(2) 487-496